A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical trial NCT07315750 · RECRUITING

Trial details

NCT number: NCT07315750
Sponsor: RemeGen Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric Carcinoma

Start date: 2026-01-01
Primary completion: 2029-06-30
Enrollment: 555

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.